Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.
暂无分享，去创建一个
D. Dunlop | C. Fegan | D. Cunningham | P. Johnson | J. Holmlund | P. Selby | T. Lissitchkov | D. Watkins | T. C. Morris | S. Rao | S. Schey | J. Oliver | D. Watkins | S. Rao | B. Hancock | D. Culligan | B. Hancock | David Cunningham | Dominic Culligan | Peter Johnson | P. Selby | Christopher Fegan | Stephen Schey